Enhanced Basal Contractility but Reduced Excitation-contraction Coupling Efficiency and Beta-adrenergic Reserve of Hearts with Increased Cav1.2 Activity
Overview
Physiology
Authors
Affiliations
Cardiac remodeling during heart failure development induces a significant increase in the activity of the L-type Ca(2+) channel (Cav1.2). However, the effects of enhanced Cav1.2 activity on myocyte excitation-contraction (E-C) coupling, cardiac contractility, and its regulation by the beta-adrenergic system are not clear. To recapitulate the increased Cav1.2 activity, a double transgenic (DTG) mouse model overexpressing the Cavbeta2a subunit in a cardiac-specific and inducible manner was established. We studied cardiac (in vivo) and myocyte (in vitro) contractility at baseline and upon beta-adrenergic stimulation. E-C coupling efficiency was evaluated in isolated myocytes as well. The following results were found: 1) in DTG myocytes, L-type Ca(2+) current (I(Ca,L)) density, myocyte fractional shortening (FS), peak Ca(2+) transients, and sarcoplasmic reticulum (SR) Ca(2+) content (caffeine-induced Ca(2+) transient peak) were significantly increased (by 100.8%, 48.8%, 49.8%, and 46.8%, respectively); and 2) cardiac contractility evaluated with echocardiography [ejection fraction (EF) and (FS)] and invasive intra-left ventricular pressure (maximum dP/dt and -dP/dt) measurements were significantly greater in DTG mice than in control mice. However, 1) the cardiac contractility (EF, FS, dP/dt, and -dP/dt)-enhancing effect of the beta-adrenergic agonist isoproterenol (2 microg/g body wt ip) was significantly reduced in DTG mice, which could be attributed to the loss of beta-adrenergic stimulation on contraction, Ca(2+) transients, I(Ca,L), and SR Ca(2+) content in DTG myocytes; and 2) E-C couplng efficiency was significantly lower in DTG myocytes. In conclusion, increasing Cav1.2 activity by promoting its high-activity mode enhances cardiac contractility but decreases E-C coupling efficiency and the adrenergic reserve of the heart.
Protein Kinase A Is a Master Regulator of Physiological and Pathological Cardiac Hypertrophy.
Bai Y, Zhang X, Li Y, Qi F, Liu C, Ai X Circ Res. 2024; 134(4):393-410.
PMID: 38275112 PMC: 10923071. DOI: 10.1161/CIRCRESAHA.123.322729.
Adrenergic Regulation of Calcium Channels in the Heart.
Papa A, Kushner J, Marx S Annu Rev Physiol. 2021; 84:285-306.
PMID: 34752709 PMC: 9573788. DOI: 10.1146/annurev-physiol-060121-041653.
PDE1 Inhibition Modulates Ca1.2 Channel to Stimulate Cardiomyocyte Contraction.
Muller G, Song J, Jani V, Wu Y, Liu T, Jeffreys W Circ Res. 2021; 129(9):872-886.
PMID: 34521216 PMC: 8553000. DOI: 10.1161/CIRCRESAHA.121.319828.
Werhahn S, Kreusser J, Hagenmuller M, Beckendorf J, Diemert N, Hoffmann S PLoS One. 2021; 16(6):e0248933.
PMID: 34138844 PMC: 8211211. DOI: 10.1371/journal.pone.0248933.
Protein Kinase Inhibitor Peptide as a Tool to Specifically Inhibit Protein Kinase A.
Liu C, Ke P, Zhang J, Zhang X, Chen X Front Physiol. 2020; 11:574030.
PMID: 33324237 PMC: 7723848. DOI: 10.3389/fphys.2020.574030.